

EUROPE INFERTILITY TESTING AND TREATMENT MARKET FORECAST 2018-2026

<https://marketpublishers.com/r/E66F1FFAB62EN.html>

Date: January 2018

Pages: 0

Price: US\$ 1,250.00 (Single User License)

ID: E66F1FFAB62EN

Abstracts

KEY FINDINGS

Europe infertility testing and treatment market captured the highest revenue share of the global market in 2017 by generating \$6190.90 million. The market is expected to lead throughout the forecast period of 2018-2026, by exhibiting a CAGR of 6.12% and collecting a net total of \$10494.53 million.

MARKET INSIGHTS

Globally, Europe is the largest market for infertility. Although the U.K market accounted for a dominant market share in 2017, other countries such as Germany, Spain, France, Nordics and Russia are fast catching up. In fact, the Nordics are expected to showcase the highest CAGR over the forecast period. The Nordic region has been a destination for fertility tourism for most couples from Europe, North America, Kenya and Hong Kong. The German infertility testing and treatment is the second fastest growing market in Europe. Increasing success rates of the IVF treatments within the region has led to significant growth in this market.

COMPETITIVE INSIGHTS

Companies like Integrated Genetics, Thermo Fisher Scientific Inc, Ovascience, Esco Micro Pte. Ltd, Halotech DNA, Genea, Roche, Irvine Scientific, Ferring Pharmaceuticals, The Cooper Companies Inc, Quest Diagnostic, Origio, Illumina Inc, Andrology Solutions, Vitrolife Ab, Centogene, Celmatrix, Merck, Elucigene, LabCorp and Endo Pharmaceuticals are well established in this region.

Contents

1. RESEARCH SCOPE

- 1.1. STUDY GOALS
- 1.2. SCOPE OF THE MARKET STUDY
- 1.3. WHO WILL FIND THIS REPORT USEFUL?
- 1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY

- 2.1. SOURCES OF DATA
 - 2.1.1. SECONDARY DATA
 - 2.1.2. PRIMARY DATA
- 2.2. TOP DOWN APPROACH
- 2.3. BOTTOM-UP APPROACH
- 2.4. DATA TRIANGULATION

3. EXECUTIVE SUMMARY

- 3.1. MARKET SUMMARY
- 3.2. KEY FINDINGS
 - 3.2.1. EUROPE IS THE LARGEST MARKET
 - 3.2.2. IVF DOMINATES THE FEMALE TREATMENT MARKET
 - 3.2.3. OXIDATIVE STRESS ANALYSIS IS THE FASTEST GROWING MALE INFERTILITY TESTING MARKET

4. MARKET OVERVIEW

- 4.1. MARKET DEFINITION
- 4.2. MARKET DRIVERS AND IMPACT
 - 4.2.1. RISE IN INFERTILITY AND TREATMENT AWARENESS
 - 4.2.2. MEDICAL TOURISM IN FERTILITY TREATMENTS
 - 4.2.3. SURROGACY LAWS ARE GETTING MORE DEFINED
 - 4.2.4. HEALTHCARE ADVANCES HAVE FINETUNED FERTILITY TREATMENT
 - 4.2.5. INCREASING EFFECTIVENESS OF TREATMENTS
 - 4.2.6. HEALTHIER DONOR EGGS
 - 4.2.7. INTRODUCTION OF NEW TESTING DEVICES
- 4.3. RESTRAINTS AND IMPACT

4.3.1. TREATMENT PROCEDURE OUT OF REACH TO MANY DUE TO COSTS INVOLVED

4.3.2. COUNTRY-WISE REGULATORY ISSUES

4.4. MARKET OPPORTUNITIES

4.4.1. REDUCING THE COST OF TREATMENT TO MAKE IT MORE ACCESSIBLE

4.4.2. IVF ATTRACTING INVESTMENTS FROM PRIVATE EQUITY INVESTORS

4.4.3. DIY TESTING INCREASING ACCESS AND REDUCING COST

4.5. MARKET CHALLENGES

4.5.1. INFERTILITY CONSIDERED A SOCIAL TABOO AMONGST MEN

4.5.2. PERILS OF MULTIPLE PREGNANCIES

4.5.3. TRADITIONAL TREATMENTS USED WIDELY AS AN ALTERNATIVE FOR INFERTILITY TREATMENTS

4.5.3.1. DIET AND SUPPLEMENTS

4.5.3.2. ACUPUNCTURE

4.5.3.3. THERAPY

4.5.3.4. QIGONG

5. INFERTILITY CAUSES

5.1. CAUSES OF MALE INFERTILITY

5.1.1. ABNORMALITY IN THE SPERM

5.1.2. ENVIRONMENTAL FACTORS

5.1.3. POOR HEALTH AND LIFESTYLE

5.2. CAUSES OF FEMALE INFERTILITY

5.2.1. OVULATION DISORDERS

5.2.2. DAMAGE TO FALLOPIAN TUBES

5.3. MORAL QUESTIONS

6. MALE INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 (\$ MILLION)

6.1. MARKET BY MALE INFERTILITY TESTING

6.1.1. DNA FRAGMENTATION

6.1.2. OXIDATIVE STRESS ANALYSIS

6.1.3. SPERM PENETRATION ASSAY

6.1.4. COMPUTER ASSISTED SEMEN ANALYSIS (CASA)

6.1.5. SPERM AGGLUTINATION

6.1.6. MICROSCOPIC EXAMINATION

6.1.7. OTHERS

6.2. MARKET BY MALE INFERTILITY TREATMENT

6.2.1. VASOVASOSTOMY AND VASOEPIDIDYMOSTOMY (VASECTOMY REVERSAL)

6.2.2. SPERM RETRIEVAL TREATMENT

6.2.3. MICROSURGICAL SPERM ASPIRATION (MESA)

6.2.4. TESTICULAR SPERM EXTRACTION (TESE)

6.2.5. VARICOCELE REPAIRS

6.2.6. ASSISTED REPRODUCTIVE TECHNIQUES (ART)

6.2.7. INTRAUTERINE INSEMINATION (IUI)

6.2.8. IN VITRO FERTILIZATION (IVF)

6.2.9. INTRACYTOPLASMIC SPERM INJECTION (ICSI)

7. FEMALE INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 (\$ MILLION)

7.1. MARKET BY FEMALE INFERTILITY TESTING

7.1.1. OVULATION TESTING

7.1.2. HYSTEROSALPINGOGRAPHY

7.1.3. LAPAROSCOPY

7.1.4. TRANSVAGINAL ULTRASOUND

7.1.5. OVARIAN RESERVE TESTING

7.1.6. HORMONAL LEVEL TESTING

7.1.7. OTHERS (GENETIC TESTING)

7.2. MARKET BY FEMALE INFERTILITY TREATMENT

7.2.1. IN VITRO FERTILIZATION

7.2.2. INTRAUTERINE INSEMINATION (IUI)

7.2.3. DRUG AND HORMONE THERAPIES

8. EUROPE INFERTILITY TESTING AND TREATMENT MARKET BY END-USERS 2018-2026 (\$ MILLION)

8.1. FERTILITY AND SURGICAL CENTERS

8.2. HOSPITALS AND RESEARCH LABORATORIES

8.3. CRYOBANKS

9. KEY ANALYTICS

9.1. PORTERS 5 FORCE MODEL

9.1.1. THREAT OF NEW ENTRANTS

- 9.1.2. THREAT OF SUBSTITUTE PRODUCTS
- 9.1.3. BARGAINING POWER OF BUYERS
- 9.1.4. BARGAINING POWER OF SUPPLIERS
- 9.1.5. INTENSITY OF COMPETITIVE RIVALRY
- 9.2. VALUE CHAIN ANALYSIS
 - 9.2.1. RAW MATERIAL PROCUREMENT
 - 9.2.2. MANUFACTURING
 - 9.2.3. SUPPLY LOGISTICS
 - 9.2.4. DISTRIBUTION CHANNELS
 - 9.2.5. END USERS
- 9.3. KEY BUYING CRITERIA
 - 9.3.1. TREATMENT OPTIONS
 - 9.3.2. QUALITY OF MEDICAL PROCEDURES
 - 9.3.3. PRICE OF TREATMENTS
 - 9.3.4. SHIFT TOWARDS MEDICAL TOURISM
 - 9.3.5. REIMBURSEMENT
- 9.4. REGULATORY FRAMEWORK
- 9.5. KEY TRENDS
 - 9.5.1. MALE INFERTILITY TREATMENT SEGMENT IS RISING
 - 9.5.2. FERTILITY TOURISM- AN IMPORTANT TREND
 - 9.5.3. UPPER MIDDLE INCOME GROUP IS THE KEY TARGET
 - 9.5.4. REGULATORY ENVIRONMENT KEY MARKET ENABLER
 - 9.5.5. MORE COUPLES OPTING FOR SURROGACY
 - 9.5.6. TECHNOLOGY ENABLING THE SUCCESS OF FERTILITY TREATMENTS
- 9.6. VENDOR LANDSCAPE
- 9.7. OPPORTUNITY MATRIX

10. KEY ANALYTICS – TESTING MARKET

- 10.1. PORTER'S 5 FORCE ANALYSIS
 - 10.1.1. THREAT OF NEW ENTRANTS
 - 10.1.2. THREAT OF SUBSTITUTE PRODUCTS
 - 10.1.3. BARGAINING POWER OF BUYERS
 - 10.1.4. BARGAINING POWER OF SUPPLIERS
 - 10.1.5. INTENSITY OF COMPETITIVE RIVALRY
- 10.2. KEY BUYING CRITERIA
- 10.3. VENDOR LANDSCAPE
- 10.4. OPPORTUNITY MATRIX

11. EUROPE INFERTILITY TESTING AND TREATMENT MARKET COUNTRY ANALYSIS 2018-2026 (\$ MILLION)

- 11.1. UK
- 11.2. GERMANY
- 11.3. FRANCE
- 11.4. NORDICS
- 11.5. RUSSIA

12. COMPETITIVE ANALYSIS

- 12.1. ANDROLOGY SOLUTIONS
 - 12.1.1. OVERVIEW
 - 12.1.2. PRODUCT PORTFOLIO
 - 12.1.3. SCOT ANALYSIS
- 12.2. ENDO PHARMACEUTICALS
 - 12.2.1. OVERVIEW
 - 12.2.2. PRODUCT PORTFOLIO
 - 12.2.3. STRATEGIC MOVES
 - 12.2.4. SCOT ANALYSIS
- 12.3. PROGYNV
 - 12.3.1. OVERVIEW
 - 12.3.2. PRODUCT PORTFOLIO
 - 12.3.3. STRATEGIC MOVES
 - 12.3.4. SCOT ANALYSIS
- 12.4. FERRING PHARMACEUTICALS
 - 12.4.1. OVERVIEW
 - 12.4.2. PRODUCT PORTFOLIO
 - 12.4.3. STRATEGIC MOVES
 - 12.4.4. SCOT ANALYSIS
- 12.5. GENEV
 - 12.5.1. OVERVIEW
 - 12.5.2. PRODUCT PORTFOLIO
 - 12.5.3. STRATEGIC MOVES
 - 12.5.4. SCOT ANALYSIS
- 12.6. HALOTECH DNA
 - 12.6.1. OVERVIEW
 - 12.6.2. PRODUCT PORTFOLIO
 - 12.6.3. STRATEGIC MOVES

- 12.6.4. SCOT ANALYSIS
- 12.7. IRVINE SCIENTIFIC
 - 12.7.1. OVERVIEW
 - 12.7.2. PRODUCT PORTFOLIO
 - 12.7.3. STRATEGIC MOVES
 - 12.7.4. SCOT ANALYSIS
- 12.8. MERCK
 - 12.8.1. OVERVIEW
 - 12.8.2. PRODUCT PORTFOLIO
 - 12.8.3. STRATEGIC MOVES
 - 12.8.4. SCOT ANALYSIS
- 12.9. ORIGIO
 - 12.9.1. OVERVIEW
 - 12.9.2. PRODUCT PORTFOLIO
 - 12.9.3. STRATEGIC MOVES
 - 12.9.4. SCOT ANALYSIS
- 12.10. OVASCIENCE
 - 12.10.1. OVERVIEW
 - 12.10.2. PRODUCT PORTFOLIO
 - 12.10.3. STRATEGIC MOVES
 - 12.10.4. SCOT ANALYSIS
- 12.11. VITROLIFE AB
 - 12.11.1. OVERVIEW
 - 12.11.2. PRODUCT PORTFOLIO
 - 12.11.3. STRATEGIC MOVES
 - 12.11.4. SCOT ANALYSIS
- 12.12. THERMO FISHER SCIENTIFIC INC
 - 12.12.1. OVERVIEW
 - 12.12.2. PRODUCT PORTFOLIO
 - 12.12.3. STRATEGIC MOVES
 - 12.12.4. SCOT ANALYSIS
- 12.13. THE COOPER COMPANIES, INC
 - 12.13.1. OVERVIEW
 - 12.13.2. PRODUCT PORTFOLIO
 - 12.13.3. STRATEGIC MOVES
 - 12.13.4. SCOT ANALYSIS
- 12.14. QUEST DIAGNOSTIC
 - 12.14.1. OVERVIEW
 - 12.14.2. PRODUCT PORTFOLIO

- 12.14.3. SCOT ANALYSIS
- 12.14.4. STRATEGIC MOVES
- 12.15. ESCO MICRO PTE. LTD.
 - 12.15.1. OVERVIEW
 - 12.15.2. PRODUCT PORTFOLIO
 - 12.15.3. STRATEGIC MOVES
 - 12.15.4. SCOT ANALYSIS
- 12.16. ELUCIGENE
 - 12.16.1. OVERVIEW
 - 12.16.2. PRODUCT PORTFOLIO
 - 12.16.3. SCOT ANALYSIS
 - 12.16.4. STRATEGIC INITIATIVE
- 12.17. ALERE
 - 12.17.1. OVERVIEW
 - 12.17.2. PRODUCT PORTFOLIO
 - 12.17.3. SCOT ANALYSIS
 - 12.17.4. STRATEGIC INITIATIVE
- 12.18. CELMATRIX
 - 12.18.1. OVERVIEW
 - 12.18.2. PRODUCT PORTFOLIO
 - 12.18.3. SCOT ANALYSIS
 - 12.18.4. STRATEGIC INITIATIVE
- 12.19. VERITAS GENETICS
 - 12.19.1. OVERVIEW
 - 12.19.2. PRODUCT PORTFOLIO
 - 12.19.3. SCOT ANALYSIS
 - 12.19.4. STRATEGIC INITIATIVE
- 12.20. CLARITAS GENOMICS
 - 12.20.1. OVERVIEW
 - 12.20.2. PRODUCT PORTFOLIO
 - 12.20.3. SCOT ANALYSIS
 - 12.20.4. STRATEGIC INITIATIVE
- 12.21. ROCHE
 - 12.21.1. OVERVIEW
 - 12.21.2. PRODUCT PORTFOLIO
 - 12.21.3. SCOT ANALYSIS
 - 12.21.4. STRATEGIC INITIATIVE
- 12.22. LABCORP
 - 12.22.1. OVERVIEW

- 12.22.2. PRODUCT PORTFOLIO
- 12.22.3. SCOT ANALYSIS
- 12.22.4. STRATEGIC INITIATIVE
- 12.23. AGILENT
 - 12.23.1. OVERVIEW
 - 12.23.2. PRODUCT PORTFOLIO
 - 12.23.3. SCOT ANALYSIS
 - 12.23.4. STRATEGIC INITIATIVE
- 12.24. INTEGRATED GENETICS
 - 12.24.1. OVERVIEW
 - 12.24.2. PRODUCT PORTFOLIO
 - 12.24.3. SCOT ANALYSIS
- 12.25. PHOSPHORUS DIAGNOSTICS
 - 12.25.1. OVERVIEW
 - 12.25.2. PRODUCT PORTFOLIO
 - 12.25.3. SCOT ANALYSIS
 - 12.25.4. STRATEGIC INITIATIVE
- 12.26. CENTOGENE
 - 12.26.1. OVERVIEW
 - 12.26.2. PRODUCT PORTFOLIO
 - 12.26.3. SCOT ANALYSIS
 - 12.26.4. STRATEGIC INITIATIVE
- 12.27. NATERA INC
 - 12.27.1. OVERVIEW
 - 12.27.2. PRODUCT PORTFOLIO
 - 12.27.3. SCOT ANALYSIS
 - 12.27.4. STRATEGIC INITIATIVE
- 12.28. ILLUMINA INC
 - 12.28.1. OVERVIEW
 - 12.28.2. PRODUCT PORTFOLIO
 - 12.28.3. SCOT ANALYSIS
 - 12.28.4. STRATEGIC INITIATIVE

List Of Tables

LIST OF TABLES

TABLE 1 EUROPE INFERTILITY TESTING AND TREATMENT MARKET BY GENDER
2018-2026 (\$ MILLION)

TABLE 2 AVERAGE COST COMPARISON OF INFERTILITY TREATMENTS

TABLE 3 EUROPE MALE INFERTILITY TESTING AND TREATMENT MARKET
2018-2026 (\$ MILLION)

TABLE 4 EUROPE MALE INFERTILITY TESTING MARKET 2018-2026(\$MILLION)

TABLE 5 PROS AND CONS OF DNA SHARING METHODS

TABLE 6 EUROPE FEMALE INFERTILITY TESTING AND TREATMENT MARKET
2018-2026 (\$ MILLION)

TABLE 7 EUROPE FEMALE INFERTILITY TESTING MARKET 2018-2026 (\$MILLION)

TABLE 8 EUROPE FEMALE INFERTILITY TREATMENT MARKET 2018-2026 (\$
MILLION)

TABLE 9 AVERAGE COST OF SOME INFERTILITY TREATMENTS

TABLE 10 SOME COMMON DRUG THERAPIES

TABLE 11 EUROPE INFERTILITY TESTING AND TREATMENT MARKET BY END-
USERS 2018-2026 (\$ MILLION)

TABLE 12 EUROPE INFERTILITY TESTING AND TREATMENT MARKET BY
COUNTRY 2018-2026 (\$MILLION)

TABLE 13 COST OF IVF IN RUSSIA

List Of Figures

LIST OF FIGURES

FIGURE 1 EUROPE INFERTILITY TESTING AND TREATMENT MARKET 2018-2026
(\$ MILLION)

FIGURE 2 MAJOR FERTILITY TREATMENT DESTINATION RANKING

FIGURE 3 CLINICAL ALGORITHM FOR THE EVALUATION OF INFERTILE WOMAN

FIGURE 4 RATE OF MULTIPLE DELIVERIES

FIGURE 5 CAUSES OF INFERTILITY

FIGURE 6 CAUSES OF INFERTILITY BASED ON GENDER

FIGURE 7 CAUSES OF SPERM DNA FRAGMENTATION

FIGURE 8 UK INFERTILITY TESTING AND TREATMENT MARKET 2018-2026
(\$MILLION)

FIGURE 9 FERTILITY TREATMENT IN 2014

FIGURE 10 GERMANY INFERTILITY TESTING AND TREATMENT MARKET
2018-2026 (\$MILLION)

FIGURE 11 FRANCE INFERTILITY TESTING AND TREATMENT MARKET 2018-2026
(\$MILLION)

FIGURE 12 NORDICS INFERTILITY TESTING AND TREATMENT MARKET
2018-2026 (\$MILLION)

FIGURE 13 RUSSIA INFERTILITY TESTING AND TREATMENT MARKET 2018-2026
(\$MILLION)

COMPANIES MENTIONED

1. ANDROLOGY SOLUTIONS
2. ENDO PHARMACEUTICALS
3. PROGYNY
4. FERRING PHARMACEUTICALS
5. GENE A
6. HALOTECH DNA
7. IRVINE SCIENTIFIC
8. MERCK
9. ORIGIO
10. OVASCIENCE
11. VITROLIFE AB
12. THERMO FISHER SCIENTIFIC INC
13. THE COOPER COMPANIES, INC

14. QUEST DIAGNOSTIC
15. ESCO MICRO PTE. LTD.
16. ELUCIGENE
17. ALERE
18. CELMATRIX
19. VERITAS GENETICS
20. CLARITAS GENOMICS
21. ROCHE
22. LABCORP
23. AGILENT
24. INTEGRATED GENETICS
25. PHOSPHORUS DIAGNOSTICS
26. CENTOGENE
27. NATERA INC
28. ILLUMINA INC

I would like to order

Product name: EUROPE INFERTILITY TESTING AND TREATMENT MARKET FORECAST 2018-2026

Product link: <https://marketpublishers.com/r/E66F1FFAB62EN.html>

Price: US\$ 1,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/E66F1FFAB62EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970